menu

Pediatric Neuroblastoma Treatment Market

Schedule Call

Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy), Risk Group (Low-Risk, Intermediate-Risk), End User (Hospitals, Cancer Specialty Centers) – Global Outlook & Forecast 2023-2031

GR - 710158 Category: Therapeutics

Number of pages: 100  |  Report Format: PDF  |  Published date: January 28, 2022

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023 to 2031


Pediatric Neuroblastoma Treatment Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 2.20 billion

Revenue Forecast in 2031

US$ 5.16 billion

CAGR

8.9%

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Treatment Type, Risk Group, End User, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global pediatric neuroblastoma treatment market was valued at US$ 2.20 billion in 2022 and is expected to register a revenue CAGR of 8.9% to reach US$ 5.16 billion by 2031.

Pediatric Neuroblastoma Treatment Market Fundamentals

Pediatric neuroblastoma is a type of cancer that develops in immature nerve cells called neuroblasts. It is the most common solid tumor found in infants and young children, typically occurring in children under the age of five. Neuroblastoma usually starts in the adrenal glands, which are located on top of the kidneys, but it can also form in nerve tissue along the spine, chest, abdomen, or pelvis. The treatment of pediatric neuroblastoma depends on several factors, including the child's age, the stage, and extent of the disease, the presence of certain genetic abnormalities, and the child’s overall health. A multidisciplinary team of healthcare professionals experienced in treating childhood cancers determines the specific treatment plan for pediatric neuroblastoma.

Pediatric Neuroblastoma Treatment Market Dynamics

Neuroblastoma is one of the most common types of childhood cancer, and its incidence has been rising over the years. The growing prevalence of pediatric neuroblastoma creates a demand for effective treatment options, driving pediatric neuroblastoma treatment market growth. According to the National Center for Biotechnology Information, neuroblastoma accounts for around 8-10% of all pediatric cancer cases. The incidence rate of neuroblastoma is 11 to 13 per million children under the age of 15, ranging from 1 per million in children aged 10-14 years old to 65 per million in children under the age of one year. Improved diagnostic methods, such as genetic testing, molecular profiling, and imaging technologies, have enhanced neuroblastoma detection and accurate staging. Early diagnosis allows for timely intervention and targeted treatment, leading to increased pediatric neuroblastoma treatment market demand. Significant advancements have been made in understanding neuroblastoma biology and treatment strategies. Targeted therapies, immunotherapies, and combination treatment regimens have shown promising results in clinical trials and have the potential to improve outcomes for pediatric neuroblastoma patients. The development of novel therapies drives the growth of the pediatric neuroblastoma treatment market. There is a growing focus on precision medicine approaches in treating pediatric neuroblastoma. Advances in genomic profiling and molecular characterization of tumors have identified specific genetic alterations and biomarkers associated with neuroblastoma. This pediatric neuroblastoma treatment industry trend towards personalized treatment approaches is expected to continue, allowing for more tailored and effective therapies. Recognizing pediatric neuroblastoma as a significant health concern has resulted in increased funding from government bodies, nonprofit organizations, and private foundations. These funds support research, clinical trials, and the development of new therapies, fostering market growth.

However, intensive treatments such as high-dose chemotherapy and stem cell transplantation can lead to significant side effects and long-term complications in pediatric neuroblastoma patients. These side effects may impact survivors' quality of life and long-term well-being, which restricts the pediatric neuroblastoma treatment market growth. Neuroblastoma cells can develop resistance to chemotherapy and targeted therapies, leading to treatment failure or disease relapse, which is also expected to hamper the pediatric neuroblastoma treatment market growth. 

Pediatric Neuroblastoma Treatment Market Ecosystem

The global pediatric neuroblastoma treatment market is analyzed from four perspectives: treatment type, risk group, end user, and region. 

Pediatric Neuroblastoma Treatment Market by Treatment Type

Based on the treatment types, the global pediatric neuroblastoma treatment market is segmented into chemotherapy, immunotherapy, targeted therapy, and others.

The chemotherapy segment accounted for the largest pediatric neuroblastoma treatment market share in 2022, it is expected to register a revenue CAGR of 9.2%. Chemotherapy has been a cornerstone of pediatric neuroblastoma treatment for many years and is considered a standard of care. It is widely used as an initial treatment to shrink tumors before surgery (neoadjuvant chemotherapy) and as a post-surgical treatment to eliminate any remaining cancer cells (adjuvant chemotherapy). It is also used in advanced or metastatic neuroblastoma cases where surgical intervention may not be feasible. Chemotherapy has shown efficacy in reducing tumor size and controlling the spread of neuroblastoma. It is a systemic treatment that can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. Chemotherapy is often combined with other treatment modalities such as surgery, radiation therapy, and immunotherapy. Combining chemotherapy with these treatments has shown improved outcomes compared to using chemotherapy alone. Chemotherapy is particularly important in treating high-risk neuroblastoma, which is associated with a higher likelihood of relapse and poorer prognosis. Intensive chemotherapy regimens, including high-dose chemotherapy with stem cell transplants, are commonly used in these cases to intensify treatment and improve survival rates. Chemotherapy is a well-established treatment modality with many drugs available for pediatric neuroblastoma. These drugs are generally accessible and have been extensively studied in clinical trials, fueling segmental growth. 

Pediatric Neuroblastoma Treatment Market by Risk Group

Based on the risk groups, the global pediatric neuroblastoma treatment market is segmented into low-risk, intermediate-risk, and high-risk.

The high-risk segment accounted for a significant revenue share of the pediatric neuroblastoma treatment market in 2022. High-risk neuroblastoma is characterized by aggressive tumor growth, early metastasis, and a higher likelihood of relapse. These factors contribute to a poorer prognosis compared to low or intermediate-risk neuroblastoma. The urgent need for effective treatment options drives the focus on the high-risk segment. High-risk neuroblastoma accounts for approximately 70% of total neuroblastoma cases globally. High-risk neuroblastoma requires more intensive treatment regimens compared to low or intermediate-risk cases. Intensive chemotherapy, high-dose chemotherapy with stem cell transplant, radiation therapy, and immunotherapy are often utilized to target the aggressive nature of high-risk neuroblastoma. High-risk neuroblastoma has been the focus of extensive research and clinical trials to identify optimal treatment approaches. This research emphasis contributes to the availability of a broader range of treatment options and advancements in the high-risk segment compared to other risk categories. High-risk neuroblastoma has gained significant attention from patient advocacy groups, healthcare organizations, and the general public. The awareness and advocacy efforts contribute to increased funding, research collaboration, and targeted initiatives to improve treatment outcomes for high-risk patients.

Pediatric Neuroblastoma Treatment Market by End User 

Based on the end users, the global pediatric neuroblastoma treatment market is segmented into hospitals, cancer specialty centers, and others.

The hospitals segment accounted for the prominent revenue share of the pediatric neuroblastoma treatment market in 2022. Hospitals provide comprehensive care facilities essential for diagnosing, treating, and managing pediatric neuroblastoma. They have the infrastructure, medical equipment, and multidisciplinary teams of healthcare professionals necessary to deliver a range of treatment modalities, including surgery, chemotherapy, radiation therapy, and supportive care. Hospitals often house specialized pediatric oncology departments or cancer centers with expertise in diagnosing and treating pediatric neuroblastoma. These specialized healthcare professionals, including pediatric oncologists, surgeons, radiologists, and radiation oncologists, are crucial in providing the specialized care required for pediatric neuroblastoma patients. Hospitals typically have access to advanced diagnostic and treatment technologies, such as imaging techniques (MRI, CT, PET scans), radiation therapy machines, and surgical facilities. These technologies are crucial for accurate diagnosis, staging, and treatment planning for pediatric neuroblastoma patients.

Pediatric Neuroblastoma Treatment Market by Region

The global pediatric neuroblastoma treatment market has been segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

The North America region has the largest pediatric neuroblastoma treatment market size in revenue generation, accounting for around 46.5% market share. Pediatric neuroblastoma has a significant prevalence in the region, which is increasing the demand for pediatric neuroblastoma treatment. According to the American Cancer Society, Neuroblastoma is by far the most frequent malignancy in newborns (those under the age of one year). Each year, approximately 700 to 800 new cases of neuroblastoma are diagnosed in the U.S. North America has a well-developed healthcare infrastructure, including hospitals, specialized pediatric oncology centers, research institutions, and clinical trial networks. This advanced infrastructure provides a strong foundation for diagnosing, treating, and managing pediatric neuroblastoma, attracting patients and healthcare professionals to the region. North America is a hub for research and development in the field of pediatric oncology, including neuroblastoma. Research institutions and academic centers collaborate with pharmaceutical companies, biotechnology firms, and government agencies to drive advancements in treatment options and innovative therapies. North America is at the forefront of technological advancements in healthcare. The region has access to state-of-the-art diagnostic imaging technologies, molecular profiling techniques, and advanced treatment modalities such as targeted therapies, immunotherapies, and precision medicine approaches. The presence of robust healthcare reimbursement systems in North America, such as Medicare and private insurance, provides financial support for pediatric neuroblastoma treatments. Adequate reimbursement mechanisms and insurance coverage reduce the financial burden on patients and their families, enabling broader access to advanced treatments and therapies. The favorable reimbursement framework promotes market growth.

Pediatric Neuroblastoma Treatment Market Competitive Landscape

The prominent players operating in the global pediatric neuroblastoma treatmentmarket are:

  • Bayer AG
  • Pfizer Inc
  • Apeiron Biologics AG
  • Baxter 
  • United Therapeutics Corporation
  • Y-mAbs Therapeutics, Inc
  • Cellectar Biosciences, Inc
  • Clarity Pharmaceuticals
  • Provectus Biopharmaceuticals, Inc
  • Scorpion Therapeutics

Pediatric Neuroblastoma Treatment Market Strategic Developments

  • In March 2023, Aptorum Group Limited announced the completion of an end-of-Phase 1 (EOP1) meeting FDA. SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients and has also received orphan drug designation previously from the US FDA. SACT-1 is an oral suspension-based repurposed small molecule drug formulated in oral suspension to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression.
  • In January 2023, AUM Biosciences Pte. Ltd. announced today that the FDA had granted a Rare Pediatric Disease Designation (RPDD) for its product candidate, AUM302. This potential first-in-class oral kinase inhibitor targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.

Frequently Asked Questions About This Report

Pediatric neuroblastoma is a type of cancer that develops in immature nerve cells called neuroblasts. It is the most common solid tumor found in infants and young children, typically occurring in children under the age of five.

Collaboration and partnerships play a significant role in advancing pediatric neuroblastoma treatment. Key market players collaborate with academic institutions, research organizations, and other industry partners to leverage their expertise, access patient populations, and jointly conduct clinical trials.

The prominent players operating in the global pediatric neuroblastoma treatment Bayer AG, Pfizer Inc, Apeiron Biologics AG, Baxter, and United Therapeutics Corporation.

The global pediatric neuroblastoma treatment market growth is estimated to grow at a revenue CAGR of 8.9% during the forecast period from 2023 to 2031.

The estimated size of the global pediatric neuroblastoma treatment market in 2031 is US$ 5.16 billion.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape 
    4. Reimbursement Scenario 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Chemotherapy
    2. Immunotherapy
    3. Targeted Therapy
    4. Others 
  6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY RISK GROUP
    1. Low-Risk
    2. Intermediate-Risk
    3. High-Risk
  7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY END USER
    1. Hospitals
    2. Cancer Specialty Center
    3. Others 
  8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Pediatric Neuroblastoma Treatment Market
      1. North America Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. North America Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. North America Pediatric Neuroblastoma Treatment Market, by End User
      4. North America Pediatric Neuroblastoma Treatment Market, by Country
        1. U.S.
          1. U.S. Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. U.S. Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. U.S. Pediatric Neuroblastoma Treatment Market, by End User
        2. Canada
          1. Canada Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Canada Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Canada Pediatric Neuroblastoma Treatment Market, by End User
    2. Europe Pediatric Neuroblastoma Treatment Market
      1. Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Europe Pediatric Neuroblastoma Treatment Market, by Risk Group 
      3. Europe Pediatric Neuroblastoma Treatment Market, by End User
      4. Europe Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. Germany
          1. Germany Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Germany Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Germany Pediatric Neuroblastoma Treatment Market, by End User 
        2. U.K.
          1. U.K. Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. U.K. Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. U.K. Pediatric Neuroblastoma Treatment Market, by End User 
        3. France
          1. France Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. France Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. France Pediatric Neuroblastoma Treatment Market, by End User
        4. Spain
          1. Spain Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Spain Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Spain Pediatric Neuroblastoma Treatment Market, by End User 
        5. Italy
          1. Italy Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Italy Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Italy Pediatric Neuroblastoma Treatment Market, by End User 
        6. Rest of Europe 
          1. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Europe Pediatric Neuroblastoma Treatment Market, by End User 
    3. Asia Pacific Pediatric Neuroblastoma Treatment Market
      1. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User
      4. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. China
          1. China Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. China Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. China Pediatric Neuroblastoma Treatment Market, by End User 
        2. Japan
          1. Japan Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Japan Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Japan Pediatric Neuroblastoma Treatment Market, by End User
        3. India
          1. India Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. India Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. India Pediatric Neuroblastoma Treatment Market, by End User 
        4. South Korea
          1. South Korea Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. South Korea Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. South Korea Pediatric Neuroblastoma Treatment Market, by End User
        5. Australia
          1. Australia Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Australia Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Australia Pediatric Neuroblastoma Treatment Market, by End User 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User 
    4. Latin America Pediatric Neuroblastoma Treatment Market
      1. Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Latin America Pediatric Neuroblastoma Treatment Market, by End User 
      4. Latin America Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. Brazil
          1. Brazil Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Brazil Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Brazil Pediatric Neuroblastoma Treatment Market, by End User 
        2. Mexico
          1. Mexico Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Mexico Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Mexico Pediatric Neuroblastoma Treatment Market, by End User
        3. Argentina
          1. Argentina Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Argentina Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Argentina Pediatric Neuroblastoma Treatment Market, by End User 
        4. Rest of Latin America
          1. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by End User
    5. Middle East & Africa Pediatric Neuroblastoma Treatment Market
      1. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
      2. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group
      3. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User 
      4. Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Country/Region
        1. GCC Countries
          1. GCC Countries Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. GCC Countries Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. GCC Countries Pediatric Neuroblastoma Treatment Market, by End User 
        2. South Africa
          1. South Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. South Africa Pediatric Neuroblastoma Treatment Market, by Risk Group 
          3. South Africa Pediatric Neuroblastoma Treatment Market, by End User
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type
          2. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group
          3. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User 
  9. COMPANY PROFILES        
    1. Bayer AG
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Pfizer Inc
    3. Apeiron Biologics AG
    4. Baxter 
    5. United Therapeutics Corporation
    6. Y-mAbs Therapeutics, Inc
    7. Cellectar Biosciences, Inc
    8. Clarity Pharmaceuticals
    9. Provectus Biopharmaceuticals, Inc
    10. Scorpion Therapeutics

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

  1. Global Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million)
  2. Global Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  3. Global Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  4. Global Pediatric Neuroblastoma Treatment Market, by Region, 2021-2031 (US$ Million) 
  5. North America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  6. North America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  7. North America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  8. North America Pediatric Neuroblastoma Treatment Market, by Country, 2021-2031 (US$ Million) 
  9. U.S. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  10. U.S. Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  11. U.S. Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  12. Canada Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  13. Canada Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  14. Canada Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  15. Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  16. Europe Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  17. Europe Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  18. Europe Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021-2031 (US$ Million) 
  19. Germany Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  20. Germany Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  21. Germany Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  22. U.K. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  23. U.K. Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  24. U.K. Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  25. France Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  26. France Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  27. France Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  28. Italy Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  29. Italy Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  30. Italy Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  31. Spain Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  32. Spain Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  33. Spain Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  34. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  35. Rest of Europe Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  36. Rest of Europe Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  37. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  38. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  39. Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  40. Asia Pacific Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021-2031 (US$ Million) 
  41. China Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  42. China Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  43. China Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  44. Japan Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  45. Japan Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  46. Japan Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  47. India Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  48. India Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  49. India Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  50. South Korea Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  51. South Korea Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  52. South Korea Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  53. Australia Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  54. Australia Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  55. Australia Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  56. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  58. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  59. Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  60. Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  61. Latin America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  62. Latin America Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021–2031 (US$ Million)
  63. Brazil Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  64. Brazil Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  65. Brazil Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  66. Mexico Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  67. Mexico Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  68. Mexico Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  69. Argentina Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  70. Argentina Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  71. Argentina Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  72. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  73. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  74. Rest of Latin America Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)
  75. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  76. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  77. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by End User 2021–2031 (US$ Million)
  78. Middle East and Africa Pediatric Neuroblastoma Treatment Market, by Country/Region, 2021–2031 (US$ Million)
  79. GCC Countries Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  80. GCC Countries Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  81. GCC Countries Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  82. South Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  83. South Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  84. South Africa Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million) 
  85. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  86. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by Risk Group, 2021–2031 (US$ Million) 
  87. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, by End User, 2021–2031 (US$ Million)

List of Figures

  1. Pediatric Neuroblastoma Treatment Market Ecosystem  
  2. Snapshot of Global Pediatric Neuroblastoma Treatment Market, 2021-2031 
  3. Snapshot of Global Pediatric Neuroblastoma Treatment Market, by Region, 2021-2031 
  4. Global Pediatric Neuroblastoma Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Pediatric Neuroblastoma Treatment Market: Key Players & Competitive Positioning (2022) 
  6. Pediatric Neuroblastoma Treatment: Market Dynamics 
  7. Global Chemotherapy for Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  8. Global Immunotherapy for Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  9. Global Targeted Therapy for Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  10. Global Others for Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  11. Global Low-Risk Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  12. Global Intermediate-Risk Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  13. Global High-Risk Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  14. Global Pediatric Neuroblastoma Treatment Market for Hospitals, 2021-2031 (US$ Million) 
  15. Global Pediatric Neuroblastoma Treatment Market for Cancer Specialty Centers, 2021-2031 (US$ Million) 
  16. Global Pediatric Neuroblastoma Treatment Market for Others, 2021-2031 (US$ Million) 
  17. North America Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  18. U.S. Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  19. Canada Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  20. Europe Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  21. Germany Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  22. U.K. Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  23. France Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  24. Italy Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  25. Spain Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  26. Rest of Europe Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  27. Asia Pacific Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  28. China Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  29. Japan Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  30. India Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  31. South Korea Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  32. Australia Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  33. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  34. Latin America Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  35. Brazil Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  36. Mexico Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  37. Argentina Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million)
  38. Rest of Latin America Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million)
  39. Middle East & Africa Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million)
  40. GCC Countries Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  41. South Africa Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million) 
  42. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market, 2021-2031 (US$ Million)
  43. Bayer AG Revenue from 2019 Onwards (US$ Million)
  44. Pfizer Inc Revenue from 2019 Onwards (US$ Million)
  45. Apeiron Biologics AG Revenue from 2019 Onwards (US$ Million)
  46. Baxter Revenue from 2019 Onwards (US$ Million)
  47. United Therapeutics Corporation Revenue from 2019 Onwards (US$ Million)
  48. Y-mAbs Therapeutics, Inc Revenue from 2019 Onwards (US$ Million)
  49. Cellectar Biosciences, Inc Revenue from 2019 Onwards (US$ Million)
  50. Clarity Pharmaceuticals Revenue from 2019 Onwards (US$ Million)
  51. Provectus Biopharmaceuticals, Inc Revenue from 2019 Onwards (US$ Million)
  52. Scorpion Therapeutics Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Pediatric Neuroblastoma Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Pediatric Neuroblastoma Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports